Literature DB >> 23709321

The use of urine drug monitoring in chronic opioid therapy: an analysis of current clinician behavior.

Zoe Clancy1, Katherine O'Connell, Joseph Couto.   

Abstract

OBJECTIVES: The purpose of this study was to better quantify how urine drug monitoring (UDM) is used in clinical practice. Little is known about which patients are monitored, how often patients are monitored, which substances are important to detect, and under what circumstances clinicians modify the frequency of monitoring.
DESIGN: An online survey was developed based on qualitative phone interviews with eight clinicians who use UDM as a routine component of clinical practice. PARTICIPANTS: One thousand fourteen randomly selected clinicians known to order urine toxicology screenings were invited by mail in June 2011 to respond to the online survey assessing their clinical needs and preferences regarding UDM.
RESULTS: Of the 93 respondents, 76 percent (n = 72) require all new patients to have UDM performed when they enter their clinic. The majority administer UDM to patients four times a year. The most common reasons cited by clinicians for a change in the frequency of monitoring are patient history of substance abuse and aberrant behaviors. Overall, the respondents showed broad support to test patients consistently for the most common illicit drugs, the majority of opioids, and a handful of prescription medications associated with abuse.
CONCLUSION: Despite a lack of agreement between guidelines informing the use of UDM, there appears to be a general consensus among practitioners that use UDM on: which patients to monitor, how often to monitor, and which substances are most important to detect.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23709321     DOI: 10.5055/jom.2013.0153

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  3 in total

1.  Methods to reduce false reporting of substance abstinence in clinical research.

Authors:  Sandra J Japuntich; Kimberly A Arditte Hall; Celina M Joos; Ann M Rasmusson; Suzanne L Pineles
Journal:  Int J Methods Psychiatr Res       Date:  2018-01-04       Impact factor: 4.035

2.  Rates of fetal polydrug exposures in methadone-maintained pregnancies from a high-risk population.

Authors:  Kaitlyn Delano; Joey Gareri; Gideon Koren
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

3.  Counselors' Clinical Use of Definitive Drug Testing Results in Their Work with Substance-Use Clients: a Qualitative Study.

Authors:  Adam Rzetelny; Barbara Zeller; Nicholas Miller; Kathy Egan City; Kenneth L Kirsh; Steven D Passik
Journal:  Int J Ment Health Addict       Date:  2015-07-21       Impact factor: 3.836

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.